Our response to COVID-19

We're supporting people to maintain their wellbeing and manage isolation.

Electroconvulsive therapy

What is electroconvulsive therapy (ECT)?

In ECT, a seizure is electrically induced after the patient has been given a short-acting anaesthetic and is asleep. Although viewed as controversial, ECT is a well established psychiatric treatment with good evidence to support its effective and safe use. ECT is most often used as a treatment for severe depression that has not responded adequately to other treatments as it has been shown to be more effective than antidepressant medication. It is also used as a first line treatment in depression where an urgent response is required as it works more quickly than medications. While most people with schizophrenia respond adequately to antipsychotic medication, some find it is not completely effective for all of their symptoms. ECT is currently used and is being further evaluated as an additional or alternative treatment for these people and is likely to be most effective for those who have depressive symptoms or have abrupt or recent onset of psychotic symptoms.

What is the evidence for ECT for people with schizophrenia?

Moderate to high quality evidence suggests a small, short-term benefit of ECT compared to sham ECT (placebo) for symptom improvement in people with schizophrenia who are or who are not being treated with antipsychotics. However, there was more memory impairment, headache, and EEG abnormalities with ECT. There is also moderate quality evidence that antipsychotics are more effective than ECT for global improvement (but not mental state).

Moderate quality evidence finds medium to large effects of greater improvement in symptom severity with adjunctive ECT in Chinese people with treatment-resistant schizophrenia. This effect lasted for around 5 weeks post-treatment.

Moderate to low quality evidence suggests small to medium-sized benefits of ECT alone over psychoanalytic psychotherapy alone for mental state, behaviour and social functioning 6 months after treatment, and for global improvement for 2 years after treatment.

August 2019

Last updated at: 4:09 am, 27th August 2019
To view documentation related to this topic download the files below
Fact Sheet Technical Commentary

NeuRA Libraries

Title Colour Legend:
Green - Topic summary is available.
Orange - Topic summary is being compiled.
Red - Topic summary has no current systematic review available.